F8 and hemophilia B: Notable examples are current Phase 3 trials for Hemophilia A and B. Early positive results from Phase 3 trials of UniQure’s AMT-061 (atranaogene dezaparvovec), an AAV5 vector with the factor IX (FIX) transgene for Hemophilia B, and BioMarin’s BMN 270 (valoctocogene roxaparvovec), an AAV5 vector with the factor XII (F8) transgene for Hemophilia A, emerged in 2021.